Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi

Amitriptyline or stabilization splint in chronic tmd patients-a pilot (CROSBI ID 614905)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Alajbeg, Iva ; Borić Brakus, Ratka ; Valentić- Peruzović, Melita Amitriptyline or stabilization splint in chronic tmd patients-a pilot // Journal of dental research. 2014. str. x-x

Podaci o odgovornosti

Alajbeg, Iva ; Borić Brakus, Ratka ; Valentić- Peruzović, Melita

engleski

Amitriptyline or stabilization splint in chronic tmd patients-a pilot

Objective: The most common clinical symptoms of temporomandibular disorders (TMD) are pain and dysfunction. The aim of this pilot study was to evaluate the effectiveness of antidepressant amitriptyline and stabilization splint on the intensity of pain and quality of life in patients with chronic TMD. Method: Thirteen patients (mean age =42.23 y) with chronic TMD were randomly allocated into 3 groups according to the prescribed therapy: 4 received active medication (25 mg of amitriptyline), 4 received placebo pills and 5 were treated with a stabilization splint. Patients were managed for 12 consecutive weeks. Follow-up evaluations were done at the 1st, 6th and 12th week of treatment. Treatment outcomes included pain as reported on visual analogue scale (VAS), pain-free maximal mouth opening (MO) and oral health related quality of life (Oral Health Impact Profile, OHIP-14). Result: At baseline of treatment there were no significant differences among the groups for VAS and OHIP-14 scores, as well as for mean pain duration. VAS scores improved significantly across time for the amitriptyline group (F=11.326, p=0.002, effect size =0.791) and stabilization splint group (F=7.343, p=0.005, effect size =0.647). The mean OHIP-14 scores decreased significantly over the time in the amitriptyline group only (F=4.417, p=0.036, effect size =0.596). In the placebo group, VAS and OHIP-14 scores did not change significantly over the time (p>0.05). Only in the stabilization splint group pain-free MO improved significantly in the 12th week, compared with the baseline (p=0.001). Conclusion: The results of this limited study support the administration of low doses of amitriptyline over a period of 12 weeks for the management of pain resulting from chronic TMD. Furthermore, stabilization splint showed to be superior in the treatment of limited mouth opening during the same period.

temporomandibular joint disorders ; antidepressant agents ; stabilization splint

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

x-x.

2014.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Journal of dental research

0022-0345

1544-0591

Podaci o skupu

"2014 IADR/PER Congress“

poster

10.09.2014-13.09.2014

Dubrovnik, Hrvatska

Povezanost rada

Dentalna medicina

Indeksiranost